A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.
Richard S. Finn
Research Funding - Eisai
Ann-Lii Cheng
Consultant or Advisory Role - Eisai
Kenji Ikeda
Honoraria - Bayer; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; Olympus Medical Systems
Expert Testimony - Eisai
Masatoshi Kudo
Honoraria - Bayer; Daiichi Sankyo; Eisai
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Corina E. Dutcus
Employment or Leadership Position - Eisai
Steven Younger
Employment or Leadership Position - Eisai
Kwang-Hyub Han
Consultant or Advisory Role - Eisai
Research Funding - Clinical Trial Research Grant
Shukui Qin
No relevant relationships to disclose
Eric Raymond
Consultant or Advisory Role - Eisai